IP in Australia: major changes in store

Just two years after one of the biggest ever shake-ups to Australian patent law—the Raising the Bar Act of 2012—further change is in store for pharmaceutical and biotechnology companies operating in Australasia.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Asia-Pacific

Australia boutique hires experienced life sciences litigator

23 February 2023 New recruit joins from DLA Piper and will head up firm’s litigation team | Previously worked on Pfizer v Samsung Bioepis, Jusand v Rattlejack & Murray Engineering, and Pfizer v Sandoz | Follows prosecutor Chris Vindurampulle who joined in October last year.

Asia-Pacific

Australian court rejects Boehringer opposition bid against MSD unit’s anti-parasitic drug patent

24 May 2022 The Federal Court of Australia has refused an appeal request in a decade-long case brought by Boehringer Ingelheim Animal Health against MSD subsidiary, Intervet International.

Asia-Pacific

Wyeth secures Australian injunction against MSD vaccine

30 November 2020 The Federal Court of Australia has granted Pfizer subsidiary Wyeth’s bid for an injunction against Merck Sharp Dohme in a dispute over vaccine patents.

More features

From Edwards to Insulet: Three key medical device cases of 2025

5 ways the USPTO director is changing US innovation

EU unveils sweeping pharma, biotech, and medical device reforms

WATCH: “Try and see” – an underestimated standard for obviousness before the EPO?

Abbott wins appeal to restore glucose monitoring patent

Regeneron v Alvotech: The big impact

Beyond traditional IP: A comprehensive AI strategy for life sciences

Prosecuting bispecific antibody patents: A cookbook for patent chefs

IP in Australia: major changes in store

More on this story

Editor's picks

Editor's picks

More features